Ann Richmond Archive — Page 1 of 2

Research by Ann Richmond, PhD, second from left, Chi Yan, PhD, left, Kensey Bergdorf, PhD, JinMing Yang, PhD, and colleagues is leading to new insights on melanoma tumor formation and growth.
June 29, 2023

Study identifies key regulator of melanoma development

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

By Tom Wilemon
February 24, 2022

Melanoma treatment response

Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

By Sarah E. Glass
July 1, 2021

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

By Tom Wilemon
Ann Richmond, MD, Chi Yan, PhD, Jinming Yang, PhD, and colleagues are studying ways to boost antitumor immunity and reduce tumor growth in breast cancer and melanoma.
December 17, 2020

Study reveals new strategy for reducing tumor growth, metastasis

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

By Leigh MacMillan
Ann Richmond, PhD, is stepping down from her role as associate director for Research Education at Vanderbilt-Ingram Cancer Center.
July 16, 2020

Richmond steps down as associate director for Research Education for VICC

After serving 16 years as associate director for Research Education at Vanderbilt-Ingram Cancer Center (VICC), Ann Richmond, PhD, Ingram Professor of Cancer Research, is stepping down from the leadership post.

By Tom Wilemon
April 23, 2020

Study explores melanoma drug’s effectiveness

A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.

By Tom Wilemon